Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Chen Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1840-5765; OpenAlex author ID A5043415657. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 4 papers · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 20

  1. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11239-w↗
  2. M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. Co-author DOI 10.1016/j.ymthe.2020.11.024↗
  3. Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2020.08.021↗
  4. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-17-3841↗
  5. Krüppel-Like Factor 4 Inhibits Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis by Down-Regulating Caveolin-1 Expression. Last author DOI 10.1159/000488426↗
  6. SMAD4 and its role in pancreatic cancer. Co-author DOI 10.1007/s13277-014-2883-z↗
  7. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Co-author DOI 10.18632/oncotarget.4124↗
  8. miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. Co-author DOI 10.3892/or.2015.3945↗
  9. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Co-author DOI 10.1016/j.bbcan.2014.01.002↗
  10. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator sys… Co-author DOI 10.1158/1078-0432.ccr-13-2311↗
  11. Analysis of the potential for pancreatic cancer metastasis in vitro and in vivo. Co-author DOI 10.1007/978-1-62703-287-2_17↗
  12. Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. First author DOI 10.1007/s10620-013-2841-4↗
  13. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-3859↗
  14. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Co-author DOI 10.3892/or.2013.2576↗
  15. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Co-author DOI 10.1016/j.cytogfr.2012.01.003↗
  16. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Co-author DOI 10.1158/0008-5472.can-11-3102↗
  17. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Co-author DOI 10.4149/neo_2012_007↗
  18. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s10620-010-1416-x↗
  19. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. First author DOI 10.1371/journal.pone.0025941↗
  20. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. Co-author DOI 10.3748/wjg.v17.i25.2992↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengjun Qiu · 11 shared papers, 2011–2023 · strength 0.81
  2. Zengya Guo · 3 shared papers, 2020–2023 · strength 0.39
  3. Yuhan Yang · 3 shared papers, 2020–2023 · strength 0.39
  4. Keping Xie · 6 shared papers, 2012–2014 · strength 0.33
  5. Peng Cao · 2 shared papers, 2021–2023 · strength 0.28
  6. Buwei Teng · 2 shared papers, 2020–2021 · strength 0.23
  7. Xiaofeng Wang · 2 shared papers, 2018–2021 · strength 0.20
  8. Haitao Gu · 1 shared paper, 2023 · strength 0.16
  9. Xuan Han · 1 shared paper, 2023 · strength 0.16
  10. Weiwei Chen · 1 shared paper, 2020 · strength 0.11
  11. Gang Cen · 2 shared papers, 2015 · strength 0.10
  12. Jiujie Cui · 2 shared papers, 2013–2014 · strength 0.09
  13. Zhonglin Zhu · 1 shared paper, 2018 · strength 0.08
  14. Guangtao Luo · 1 shared paper, 2018 · strength 0.08
  15. Jin Dou · 1 shared paper, 2018 · strength 0.08
  16. Jing Zhang · 1 shared paper, 2018 · strength 0.08
  17. Xiu-Hong Lv · 2 shared papers, 2011–2013 · strength 0.07
  18. Jiawei Du · 1 shared paper, 2014 · strength 0.07
  19. Liwei Wang · 2 shared papers, 2012–2013 · strength 0.06
  20. Lei Li · 1 shared paper, 2015 · strength 0.05
  21. Xinjian Wan · 1 shared paper, 2015 · strength 0.05
  22. Baiwen Li · 1 shared paper, 2015 · strength 0.05
  23. Xiang Xia · 1 shared paper, 2015 · strength 0.05
  24. Dacheng Xie · 1 shared paper, 2014 · strength 0.05
  25. Yong Gao · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.